These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1366314)

  • 1. [Antithrombin III in chronic renal insufficiency].
    Bekić-Kaluza S; Macanović M
    Med Arh; 1991; 45(1-2):3-8. PubMed ID: 1366314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal pathology in the Ivory Coast: exploration and functional activity of antithrombin iii].
    Blavy G; Kouame C
    Nephrologie; 1994; 15(6):387-9. PubMed ID: 7862227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.
    Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M
    Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III in uremia.
    Jørgensen KA; Stoffersen E
    Scand J Urol Nephrol; 1979; 13(3):299-303. PubMed ID: 531528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antithrombin III and heparinemia in patients on hemodialysis].
    Nagami AE; Sesin AM; Nattero GN
    Rev Fac Cien Med Univ Nac Cordoba; 1988; 46(1):23-6. PubMed ID: 3273332
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of hemodialysis and peritoneal dialysis on antithrombin III and platelets.
    Woo KT; Wei SS; Lee EJ; Lau YK; Lim CH
    Nephron; 1985; 40(1):25-8. PubMed ID: 4000334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma antithrombin III concentration in patients on regular haemodialysis treatment.
    Jørgensen M; Eriksen HO; Tranebjaerg L
    Nephron; 1985; 40(1):22-4. PubMed ID: 4000333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antithrombin III activity during hemodialysis].
    Rydzewski A; Soszka J; Myśliwiec M
    Pol Arch Med Wewn; 1983 Feb; 69(2):123-8. PubMed ID: 6889150
    [No Abstract]   [Full Text] [Related]  

  • 9. [Acute effects of sulodexide on the lipid profile and on antithrombin III in patients with chronic renal insufficiency in hemodialysis treatment].
    Averna MR; Citarella P; Picone F; Capodicasa G; Galione A; Rini G; Notarbartolo A
    Clin Ter; 1984 Jan; 108(2):111-4. PubMed ID: 6232045
    [No Abstract]   [Full Text] [Related]  

  • 10. Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.
    Matsuo T; Yamada T; Yamanashi T; Kodama K
    Clin Lab Haematol; 1989; 11(3):213-9. PubMed ID: 2686903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin deficiency in end-stage renal disease associated with paraplegia: effect of hemodialysis.
    Vaziri ND; Winer RL; Alikhani S; Danviryasup K; Toohey J; Hung E; Gordon S; Eltorai I; Paule P
    Arch Phys Med Rehabil; 1985 May; 66(5):307-9. PubMed ID: 3924003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hemodialysis on protein C, protein S, and antithrombin III levels.
    Lai KN; Yin JA; Yuen PM; Li PK
    Am J Kidney Dis; 1991 Jan; 17(1):38-42. PubMed ID: 1824735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure.
    Langley PG; Keays R; Hughes RD; Forbes A; Delvos U; Williams R
    Hepatology; 1991 Aug; 14(2):251-6. PubMed ID: 1860682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of serum level of antithrombin-III antigen, antithrombin activity, and its ratio of AT-III-heparin complex formation in maintenance hemodialysis patients].
    Yoshida K; Saka M; Kaneko Y; Kubota K; Hirao Y; Okajima E; Ishida M; Kihouin K; Motomiya Y
    Nihon Jinzo Gakkai Shi; 1989 Nov; 31(11):1171-7. PubMed ID: 2625740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
    Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
    Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant therapy in a congenital antithrombin III (ATIII)-deficient patient with chronic renal failure undergoing regular hemodialysis.
    Matsuo T; Yamada T; Matsuo M; Sakai R
    Biomater Artif Cells Immobilization Biotechnol; 1991; 19(1):185-91. PubMed ID: 1751668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of antithrombin III in kidney diseases].
    Schrader J; Köstering H; Scheler F
    Behring Inst Mitt; 1986 Feb; (79):216-30. PubMed ID: 3718408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin-III activity in chronic renal failure.
    Gupta V; Verma SL; Bhardwaj KL; Singh JP
    J Assoc Physicians India; 1986 Aug; 34(8):572-3. PubMed ID: 3793678
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
    Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
    Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.